Ligand selectivity hotspots in serotonin GPCRs.


Journal

Trends in pharmacological sciences
ISSN: 1873-3735
Titre abrégé: Trends Pharmacol Sci
Pays: England
ID NLM: 7906158

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 02 09 2023
revised: 20 09 2023
accepted: 28 09 2023
medline: 20 11 2023
pubmed: 2 11 2023
entrez: 1 11 2023
Statut: ppublish

Résumé

Serotonin is a neurotransmitter regulating numerous physiological processes also modulated by drugs, for example, schizophrenia, depression, migraine, and obesity. However, these drugs typically have adverse effects caused by promiscuous binding across 12 serotonin and more than 20 homologous receptors. Recently, structures of the entire serotonin receptor family uncovered molecular ligand recognition. Here, we present a map of 19 'selectivity hotspots', that is, nonconserved binding site residues governing selectivity via favorable target interactions or repulsive 'off-target' contacts. Furthermore, we review functional rationale from observed ligand-binding affinities and mutagenesis effects. Unifying knowledge underlying specific probes and drugs is critical toward the functional characterization of different receptors and alleviation of adverse effects.

Identifiants

pubmed: 37914598
pii: S0165-6147(23)00214-6
doi: 10.1016/j.tips.2023.09.012
pii:
doi:

Substances chimiques

Receptors, G-Protein-Coupled 0
Serotonin 333DO1RDJY
Ligands 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

978-990

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests D.E.G. has a part-time employment at Kvantify. A.A.J. is co-founder and co-owner of the company Lophora ApS.

Auteurs

Icaro A Simon (IA)

Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.

Walden E Bjørn-Yoshimoto (WE)

Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.

Kasper Harpsøe (K)

Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.

Stylianos Iliadis (S)

Centre for Endocrinology, William Harvey Research Institute, Bart's and the London School of Medicine and Dentistry, University of London, London EC1M 6BQ, UK.

Bo Svensson (B)

SARomics Biostructures AB, Scheelevägen 2, 223 63 Lund, Sweden.

Anders A Jensen (AA)

Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.

David E Gloriam (DE)

Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark. Electronic address: david.gloriam@sund.ku.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH